Other

Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months

AbbVie Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months increased by 9.5% to $23.00M in Q1 2026 compared to the prior quarter.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ1 2025
Last reportedQ1 2026May 8, 2026
Metric ID: other_treasury_lock_cash_flow_hedge_gain_losstobe_reclas_ead365

Historical Data

4 periods
 Q1 '25Q2 '25Q3 '25Q1 '26
Value$21.00M$21.00M$21.00M$23.00M
QoQ Change—+0.0%+0.0%+9.5%
YoY Change———+9.5%
Range$21.00M – $23.00M
Avg YoY Growth+9.5%
Median YoY Growth+9.5%
Current Streak3+ quarters growth

Frequently Asked Questions

What is AbbVie's pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months?
AbbVie (ABBV) reported pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months of $23.00M in Q1 2026.